Delving into the Latest Updates on Biosyn, Inc. with Synapse

概览

关联

1

项与 Biosyn, Inc. 相关的药物

Glyminox

靶点

Membrane lipids

作用机制

膜脂质抑制剂

在研机构-

原研机构

Biosyn, Inc.

在研适应症-

非在研适应症

HIV感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Biosyn, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Biosyn, Inc. 相关的专利（医药）

登录后查看更多信息

7

项与 Biosyn, Inc. 相关的文献（医药）

2007-03-01·Journal of Pharmaceutical Sciences3区 · 医学

Biophysical Analysis of Prototype Microbicidal Gels

3区 · 医学

Article

作者: Roger L. Schnaare ; David F. Katz ; Anthony R. Geonnotti ; Jennifer J. Peters ; Derek H. Owen ; Sarah L. Kieweg

The objective of this study was to evaluate the distribution and retention (deployment) of four prototype vehicles for delivery of prophylactic microbicides against vaginal HIV transmission. Study gels were created with different molecular compositions, producing different biophysical properties governing vaginal deployment. The study employed three techniques: direct rheological measurement of gel properties, direct observation of gel surface coating erosion, and dissolution by a vaginal fluid simulant, and mathematical modeling of gel squeezing flow processes. Results suggest significant differences in extent of vaginal coating after gel application and in erosion of these gel layers due to contact with ambient vaginal fluid and shearing. The relationships between gel rheological properties, coating flow and erosion of coating were not always anticipated from differences in gel molecular composition.

2005-10-01·AIDS Research and Human Retroviruses4区 · 医学

In Vitroandin VivoCharacterization of a Potential Universal Placebo Designed for Use in Vaginal Microbicide Clinical Trials

4区 · 医学

Article

作者: Cohl, Gina ; Buckheit, Robert W. ; Schnaare, Roger L. ; Kang, Feirong ; Romano, Joseph W. ; Douville, Karen ; Moench, Thomas R. ; McCormick, Timothy J. ; Tien, Deborah ; Lewis, Mark G. ; Watson, Karen ; Doncel, Gustavo ; Schwartz, Jill

The development of vaginal microbicides for the prevention of sexual transmission of HIV is becoming an increasingly important strategy in the battle against the AIDS epidemic. Several first generation microbicide candidates are entering Phase III efficacy trials, and several other candidates are in earlier stages of clinical development. The capacity to make accurate clinical assessments of the safety and efficacy of microbicide formulations is critical. Since microbicide trials will rely on a blinded, randomized, placebo-controlled design, it is important to employ a placebo formulation that does not distort either safety or efficacy assessments. Efficacy of the microbicide would be underestimated if the placebo itself provided a degree of protection. Conversely, a placebo with epithelial toxicity that increased susceptibility would cause an overestimation of microbicide efficacy. To address these issues, a hydroxyethylcellulose (HEC) placebo formulation has been developed and has been adopted for use in clinical evaluations of investigational microbicides as a "universal" placebo. In this report, the chemical and physical properties of this formulation are described, as well as its in vitro and in vivo effects on safety and efficacy. The results show that this "universal" placebo has adequate physical properties, is sufficiently stable as a vaginal gel formulation, and is safe and sufficiently inactive for use in the clinical study of investigational microbicides.

2005-09-01·Journal of Virology2区 · 医学

The Nonnucleoside Reverse Transcriptase Inhibitor UC-781 Inhibits Human Immunodeficiency Virus Type 1 Infection of Human Cervical Tissue and Dissemination by Migratory Cells

2区 · 医学

Article

作者: Romano, Joseph ; Shattock, Robin ; Griffin, George ; Kiselyeva, Yana ; Margolis, Leonid ; Wallace, Greg ; Fletcher, Patricia

ABSTRACTHeterosexual transmission of human immunodeficiency virus remains the major route of transmission worldwide; thus, there is an urgent need for additional prevention strategies, particularly those that could be controlled by women. Using cellular and tissue explant models, we have evaluated the potential activity of thiocarboxanilide nonnucleoside analogue reverse transcriptase inhibitor UC-781 as a vaginal microbicide. We were able to demonstrate a potent dose-dependent effect against R5 and X4 infections of T cells. In human cervical explant cultures, UC-781 was not only able to inhibit direct infection of mucosal tissue but was able to prevent dissemination of virus by migratory cells. UC-781 formulated into a carbopol gel (0.1%) retained significant activity against both direct tissue infection and transinfection mediated by migratory cells. Furthermore, UC-781 demonstrated prolonged inhibitory effects able to prevent both localized and disseminated infections up to 6 days post compound treatment. Additional studies were carried out to determine the concentration of compound that might be required to block a primary infection within draining lymph nodes. While a greater dose of compound was required to inhibit both X4 and R5 infections of lymphoid versus cervical explants, this was equivalent to a 1:3,000 dilution of the 0.1% formulation. Furthermore, a 2-h exposure to the compound prevented infection of lymphoid tissue when challenged up to 2 days later. The prolonged protection observed following pretreatment of both genital and lymphoid tissues with UC-781 suggests that this class of inhibitors may have unique advantages over other classes of potential microbicide candidates.

100 项与 Biosyn, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Biosyn, Inc. 相关的转化医学

登录后查看更多信息